The Expanding Number of Actionable Driver Mutations for NSCLC. How are They Revealed by Current & Emerging Molecular Tests? What are Their Standards of Care and Other Treatment Options?

The Expanding Number of Actionable Driver Mutations for NSCLC. How are They Revealed by Current & Emerging Molecular Tests? What are Their Standards of Care and Other Treatment Options? is organized by BioMedical Learning Institute (BMLI).

Start Date: 09/15/2020
Date Expires: 09/15/2021

CME Accreditation
Physicians:
The BioMedical Learning Institute designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses:
The BioMedical Learning Institute designates this educational activity for 2 contact hours.

Pharmacists:
Credits: 2 hours (0.2 ceu)

Other:
Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 2 hours of Category 1 credit for attending this symposium.

Overview:
The overall objective of this activity is to prepare the lung cancer community to help close many critically important Quality Performance Practice Gaps that affect all newly-diagnosed NSCLC patients by providing: 1) an improved understanding of the large number of current, emerging and evolving molecular tests for all treatment-naïve NSCLC patients, 2) knowing the corresponding FDA standards of care for all of the NSCLC driver mutations detected by these tests, 3) knowing the corresponding NGS tissue and liquid biopsy tests for newly-diagnosed NSCLC patients without mutations, and, their therapeutic standards of care options with checkpoint inhibition therapies, and, 4) understanding how to use molecular diagnostic tests to select the optimal investigational therapies in clinical trials, and, how to use FDA-approved drugs as “investigational agents” for the newly-diagnosed NSCLC patients with uncommon driver mutations, and, for the very large number of NSCLC patients without mutations, in order to produce better patient outcomes.

Learning Objectives:
Physician:
• Devise molecular testing protocols for your institution or practice based upon established guidelines, to detect actionable driver mutations, including tissue agnostic markers and PD-L1 levels, in both treatment-naïve and previously-treated NSCLC patients, and, prepare corresponding treatment algorithms utilizing optimal targeted or immune therapies.
• Implement a long-term clinical plan to increase the use of molecular diagnostic testing according to established guidelines at your institution or practice, for NSCLC patients who are newly-diagnosed, and for NSCLC patients with disease progression.
• Compare and contrast the clinical applications of plasma NGS testing versus tissue-based NGS testing in NSCLC as guidelines for systemic therapies using TKIs and immune checkpoint inhibitors.
• Understand the advantages and limitations of different liquid biopsy analytes for NSCLC, including ctDNA, CTCs, CCfDNA, ccfRNA, and other platforms for detecting driver mutations and PD-L1 levels.
• Describe the rationale for the standards of care TKIs used for treating the established actionable driver mutations such as EGFR, ALK, ROS1, BRAF and tissue agnostic patients with driver mutations such as NTRK.
• Evaluate the efficacy and safety using investigational agents and also investigational use of FDA-approved drugs for NSCLC patients with uncommon actionable driver mutations such as MET, RET, KRAS, HER2, Exon 20 and other uncommon EGFR Alterations.

Nurse:
• Devise molecular testing protocols for your institution or practice based upon established guidelines, to detect actionable driver mutations, including tissue agnostic markers” and PD-L1 levels, in both treatment-naïve and previously-treated NSCLC patients, and, prepare corresponding treatment algorithms utilizing optimal targeted or immune therapies.
• Implement a long-term clinical plan to increase the use of molecular diagnostic testing according to established guidelines at your institution or practice, for NSCLC patients who are newly-diagnosed, and for NSCLC patients with disease progression.
• Compare and contrast the clinical applications of plasma NGS testing versus tissue-based NGS testing in NSCLC as guidelines for systemic therapies using TKIs and immune checkpoint inhibitors.
• Understand the advantages and limitations of different liquid biopsy analytes for NSCLC, including ctDNA, CTCs, CCfDNA, ccfRNA, and other platforms for detecting driver mutations and PD-L1 levels.
• Describe the rationale for the standards of care TKIs used for treating the established actionable driver mutations such as EGFR, ALK, ROS1, BRAF and tissue agnostic patients with driver mutations such as NTRK.
• Evaluate the efficacy and safety using investigational agents and also “investigational use” of FDA-approved drugs for NSCLC patients with uncommon actionable driver mutations such as MET, RET, KRAS, HER2, Exon 20 and other uncommon EGFR Alterations.

Pharmacist:
• Devise molecular testing protocols for your institution or practice based upon established guidelines, to detect actionable driver mutations, including tissue agnostic markers and PD-L1 levels, in both treatment-naïve and previously-treated NSCLC patients, and, prepare corresponding treatment algorithms utilizing optimal targeted or immune therapies.
• Implement a long-term clinical plan to increase the use of molecular diagnostic testing according to established guidelines at your institution or practice, for NSCLC patients who are newly-diagnosed, and for NSCLC patients with disease progression.
• Compare and contrast the clinical applications of plasma NGS testing versus tissue-based NGS testing in NSCLC as guidelines for systemic therapies using TKIs and immune checkpoint inhibitors.
• Understand the advantages and limitations of different liquid biopsy analytes for NSCLC, including ctDNA, CTCs, CCfDNA, ccfRNA, and other platforms for detecting driver mutations and PD-L1 levels.
• Describe the rationale for the standards of care TKIs used for treating the established actionable driver mutations such as EGFR, ALK, ROS1, BRAF and tissue agnostic patients with driver mutations such as NTRK.
• Evaluate the efficacy and safety using investigational agents and also investigational use of FDA-approved drugs for NSCLC patients with uncommon actionable driver mutations such as MET, RET, KRAS, HER2, Exon 20 and other uncommon EGFR Alterations.